fluoxetine has been researched along with Acute Post-Traumatic Stress Disorder in 75 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "PTSD was induced by the single prolonged stress (SPS) model." | 5.91 | Effect of combination fluoxetine and exercise on prefrontal BDNF, anxiety-like behavior and fear extinction in a female rat model of post-traumatic stress disorder (PTSD): a comparison with male animals. ( Akhoundzadeh, K; Nikkhah, F; Shafia, S, 2023) |
| "Fluoxetine and PLX3397 were administered." | 5.72 | Fluoxetine protects against inflammation and promotes autophagy in mice model of post-traumatic stress disorder. ( Amin, N; Chen, Y; Fang, M; Fang, Z; Lou, C; Ye, S, 2022) |
| " Therefore, in this study, we combined subchronic fluoxetine (Flx) with 7-nitroindazole (NI), a selective nNOS inhibitor, and evaluated their efficacy against anxiety-related behavior in an animal model of PTSD." | 4.31 | Neuronal nitric oxide synthase inhibition accelerated the removal of fluoxetine's anxiogenic activity in an animal model of PTSD. ( Chamanara, M; Dehpour, AR; Fekrvand, S; Foroutani, L; Hemmati, S; Hosseini, Y; Nassireslami, E; Sadeghi, MA; Yousefi Zoshk, M; Yousefi-Manesh, H, 2023) |
| "The study demonstrated that tianeptine is as effective as fluoxetine in the treatment of PTSD, with even stronger effect on anxiety and equal tolerance." | 3.77 | Tianeptine in the combined treatment of combat related posttraumatic stress disorder. ( Frančišković, T; Janović, S; Letica-Crepulja, M; Nemčić-Moro, I; Rončević-Gržeta, I; Stevanović, A; Suković, Z, 2011) |
| "Eighty-eight PTSD subjects diagnosed according to DSM-IV criteria were randomly assigned to EMDR, fluoxetine, or pill placebo." | 2.73 | A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. ( Blaustein, ME; Hopper, EK; Hopper, JW; Korn, DL; Simpson, WB; Spinazzola, J; van der Kolk, BA, 2007) |
| "Fluoxetine was well tolerated at a mean daily dose of 65 mg." | 2.72 | Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: Analysis of the veteran group of a placebo-controlled, randomized clinical trial. ( Martenyi, F; Soldatenkova, V, 2006) |
| "Treatment of PTSD significantly improved resilience and reduced symptoms in this sample." | 2.71 | Trauma, resilience and saliostasis: effects of treatment in post-traumatic stress disorder. ( Connor, KM; Davidson, JR; Foa, EB; Hertzberg, MA; Payne, VM; Rothbaum, BO; Weisler, RH, 2005) |
| "The Clinician-Administered PTSD Scale, the 21-item Hamilton Rating Scale for Depression, and the Clinical Global Impressions-Severity of Illness scale were administered every 2 weeks, and self-assessments were performed with a 100 mm visual analog mood scale." | 2.70 | Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder. ( Agid, O; Lerer, B; Shalev, AY, 2001) |
| "Sixty-five patients with PTSD enrolled in one of two identical-protocol, 12-week studies and received double-blind fluoxetine or placebo." | 2.70 | Tolerability of fluoxetine in posttraumatic stress disorder. ( Barnett, SD; Connor, KM; Davidson, JR; Hertzberg, MA; Sutherland, SM; Tharwani, HM, 2002) |
| "Fluoxetine was associated with a greater improvement from baseline in total TOP-8 score than was placebo." | 2.70 | Fluoxetine versus placebo in posttraumatic stress disorder. ( Brown, EB; Koke, SC; Martenyi, F; Prakash, A; Zhang, H, 2002) |
| "Overall, PTSD was associated with greatly reduced quality of life, but considerable improvement was achieved through treatment." | 2.69 | Quality of life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo-controlled trial of fluoxetine. ( Connor, KM; Davidson, JR; Davison, RM; Malik, ML; Smith, RD; Sutherland, SM, 1999) |
| "Fluoxetine was more effective than placebo on most measures at week 12, including global improvement (much or very much improved: fluoxetine 85%, placebo 62%, difference 0." | 2.69 | Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. ( Connor, KM; Davidson, JR; Malik, ML; Sutherland, SM; Tupler, LA, 1999) |
| "A subgroup of PTSD patients received either fluoxetine or placebo in a clinical trial, and a significant SPAN score improvement was observed on fluoxetine." | 2.69 | Derivation of the SPAN, a brief diagnostic screening test for post-traumatic stress disorder. ( Churchill, E; Davidson, JR; Meltzer-Brody, S, 1999) |
| "To apply this tool to PTSD patients treated with selective serotonin re-uptake inhibitors in order to assess the impact of such treatment on the autonomic dysregulation characterizing these patients." | 2.69 | Normalization of heart rate variability in post-traumatic stress disorder patients following fluoxetine treatment: preliminary results. ( Cohen, H; Kaplan, Z; Kotler, M; Matar, M, 2000) |
| "Fluoxetine and placebo were studied in a population of combat veterans with severe, chronic PTSD." | 2.69 | Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. ( Beckham, JC; Davidson, JR; Feldman, ME; Hertzberg, MA; Kudler, HS, 2000) |
| "Fluoxetine is an effective pharmacotherapeutic agent for treating PTSD and its associated features, particularly in patients without chronic treatment histories." | 2.67 | Fluoxetine in posttraumatic stress disorder. ( Berkowitz, R; Dreyfuss, D; Fisler, R; Michaels, M; Saxe, G; Shera, D; van der Kolk, BA, 1994) |
| "Post-traumatic stress disorder (PTSD) may affect 10% of women and 5% of men at some stage, and symptoms may persist for several years." | 2.46 | Post-traumatic stress disorder. ( Bisson, JI, 2010) |
| "Posttraumatic stress disorder (PTSD) is a prevalent and disabling condition." | 2.41 | Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome. ( Davidson, JR, 2000) |
| "bromocriptine)." | 2.39 | Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. ( Anton, RF, 1996) |
| "PTSD was induced by the single prolonged stress (SPS) model." | 1.91 | Effect of combination fluoxetine and exercise on prefrontal BDNF, anxiety-like behavior and fear extinction in a female rat model of post-traumatic stress disorder (PTSD): a comparison with male animals. ( Akhoundzadeh, K; Nikkhah, F; Shafia, S, 2023) |
| "Two weeks after inducing PTSD by single-prolonged stress(SPS) in rats, the positive control group was given fluoxetine hydrochloride capsule by gavage, the low, medium, and high-dose groups were given Ganmai Dazao Decoction by gavage, and both the normal group and the model group were given the same volume of normal saline by gavage, each for 7 days." | 1.91 | [Effect of Ganmai Dazao Decoction on ethology of rats with PTSD and its mechanism]. ( Dong, JJ; Guo, JY; Tong, HY; Wang, LL; Wu, Y; Yang, HY; Zhang, J; Zheng, YM; Zhu, QJ, 2023) |
| "Posttraumatic stress disorder (PTSD) is common, with a lifetime prevalence of approximately 6%." | 1.91 | Posttraumatic Stress Disorder: Evaluation and Treatment. ( Kelley, L; Laschober, R; Sartor, Z, 2023) |
| "Fluoxetine and PLX3397 were administered." | 1.72 | Fluoxetine protects against inflammation and promotes autophagy in mice model of post-traumatic stress disorder. ( Amin, N; Chen, Y; Fang, M; Fang, Z; Lou, C; Ye, S, 2022) |
| "Animals with PTSD-like symptoms showed an increase in the number of flinches in the formalin test and a reduction in mechanical threshold in the von Frey test at both retention intervals." | 1.62 | Post-traumatic stress disorder increases pain sensitivity by reducing descending noradrenergic and serotoninergic modulation. ( de Souza, GR; Giusti-Paiva, A; Kalil-Cutti, B; Vieira, JS; Vilela, FC, 2021) |
| "It is important that prescribing for PTSD is evidence-based." | 1.56 | Evidence-based prescribing for post-traumatic stress disorder. ( Baker, A; Bisson, JI; Dekker, W; Hoskins, MD, 2020) |
| "The fluoxetine treatments reduced only the BLA's c-Fos expression." | 1.56 | Basolateral Amygdala but Not Medial Prefrontal Cortex Contributes to Chronic Fluoxetine Treatments for PTSD Symptoms in Mice. ( Huang, ACW; Ou, CY; Shyu, BC; Yu, YH, 2020) |
| "Post-traumatic stress disorder (PTSD) is a mental disorder characterized by symptoms of persistent anxiety arising after exposure to traumatic events." | 1.51 | Methyl-CpG binding protein 2 functional alterations provide vulnerability to develop behavioral and molecular features of post-traumatic stress disorder in male mice. ( Cosentino, L; De Filippis, B; Flor, H; Fuso, A; Lucarelli, M; Medici, V; Vigli, D, 2019) |
| "Treatment with fluoxetine for 7 days, but not 24 hours, also reinstated social interaction behavior in mice that were susceptible to chronic social defeat." | 1.48 | Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine. ( Berton, O; Browne, CA; Falcon, E; Lucki, I; Robinson, SA, 2018) |
| "Using a rat model of childhood-induced PTSD, pre-pubertal stress (juvenile stress, JVS), we compared the therapeutic effects of fluoxetine and examined the effectiveness of 1 month of fluoxetine treatment following JVS and into adulthood compared to treatment in adulthood." | 1.46 | Fluoxetine treatment is effective in a rat model of childhood-induced post-traumatic stress disorder. ( Ariel, L; Edut, S; Inbar, S; Richter-Levin, G, 2017) |
| "Post-traumatic stress disorder (PTSD) is a condition that develops after an individual has experienced a major trauma." | 1.46 | Effects of moderate treadmill exercise and fluoxetine on behavioural and cognitive deficits, hypothalamic-pituitary-adrenal axis dysfunction and alternations in hippocampal BDNF and mRNA expression of apoptosis - related proteins in a rat model of post-tr ( Bandegi, AR; Hosseini-Khah, Z; Mohammadkhani, R; Rafiei, A; Rashidy-Pour, A; Samaei, SA; Shafia, S; Vafaei, AA; Valadan, R, 2017) |
| "Fluoxetine was found to improve the anxiety-related symptoms of PTSD patients." | 1.42 | Effects of fluoxetine on the amygdala and the hippocampus after administration of a single prolonged stress to male Wistar rates: In vivo proton magnetic resonance spectroscopy findings. ( Han, F; Shi, Y; Wen, L; Xiao, B, 2015) |
| "In the experiment, before the PTSD animal model was developed, Rg1 (10, 5, and 2." | 1.42 | Preventive effects of ginsenoside Rg1 on post-traumatic stress disorder (PTSD)-like behavior in male C57/B6 mice. ( Chen, L; Huang, Y; Ou Yang, L; Wang, Z; Zhao, Y; Zhu, K, 2015) |
| "Adolescent trauma (AT) is a common risk factor for adult-onset posttraumatic stress disorder (PTSD)." | 1.39 | Temporal association of elevated cholecystokininergic tone and adolescent trauma is critical for posttraumatic stress disorder-like behavior in adult mice. ( Chen, Q; Jiao, J; Joseph, A; Mamiya, T; Tang, M; Tang, YP; Yang, LL; Yu, N, 2013) |
| "We show here that a PTSD-like syndrome in mice is accompanied by a long-lasting reduction of hippocampal synaptic proteins which interestingly correlates with the strength of the generalized and conditioned fear response but not with the intensity of hyperarousal symptoms." | 1.38 | Long-lasting hippocampal synaptic protein loss in a mouse model of posttraumatic stress disorder. ( Buell, DR; Golub, Y; Henes, K; Herrmann, L; Holsboer, F; Ionescu, IA; Schmidt, U; Wang, NX; Wotjak, CT, 2012) |
| "Using a model of repeated trauma in rats, we observed significant spatial memory impairment together with significantly increased 5HT(1A) receptor density (B(max)), decreased 5HT(1A) receptor affinity (K(d)), and significantly increased 5HT(2A) receptor affinity on day 7 poststress." | 1.32 | Serotonin and stress: protective or malevolent actions in the biobehavioral response to repeated trauma? ( Brand, L; Harvey, BH; Naciti, C; Stein, DJ, 2004) |
| "Therapy reduced PTSD symptoms, provoked anxiety and heart rate." | 1.31 | Brain function in a patient with torture related post-traumatic stress disorder before and after fluoxetine treatment: a positron emission tomography provocation study. ( Fernandez, M; Fischer, H; Frans, O; Fredrikson, M; Pissiota, A; von Knorring, L, 2001) |
| "Prevalence rates of PTSD and subthreshold PTSD with impairment were 2." | 1.31 | Davidson Trauma Scale (DTS): normative scores in the general population and effect sizes in placebo-controlled SSRI trials. ( Connor, KM; Davidson, JR; Tharwani, HM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (22.67) | 18.2507 |
| 2000's | 26 (34.67) | 29.6817 |
| 2010's | 22 (29.33) | 24.3611 |
| 2020's | 10 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lou, C | 1 |
| Fang, M | 2 |
| Ye, S | 1 |
| Fang, Z | 1 |
| Amin, N | 1 |
| Chen, Y | 1 |
| Sadeghi, MA | 1 |
| Hemmati, S | 1 |
| Yousefi-Manesh, H | 1 |
| Fekrvand, S | 1 |
| Foroutani, L | 1 |
| Nassireslami, E | 1 |
| Yousefi Zoshk, M | 1 |
| Hosseini, Y | 1 |
| Dehpour, AR | 1 |
| Chamanara, M | 1 |
| Shafia, S | 2 |
| Nikkhah, F | 1 |
| Akhoundzadeh, K | 1 |
| Zhang, J | 1 |
| Dong, JJ | 1 |
| Zhu, QJ | 1 |
| Zheng, YM | 1 |
| Tong, HY | 1 |
| Wu, Y | 1 |
| Wang, LL | 1 |
| Yang, HY | 1 |
| Guo, JY | 1 |
| Sartor, Z | 1 |
| Kelley, L | 1 |
| Laschober, R | 1 |
| Ben-Azu, B | 1 |
| Adebayo, OG | 1 |
| Moke, EG | 1 |
| Omogbiya, AI | 1 |
| Oritsemuelebi, B | 1 |
| Chidebe, EO | 1 |
| Umukoro, E | 2 |
| Nwangwa, EK | 1 |
| Etijoro, E | 1 |
| Mamudu, EJ | 1 |
| Chukwuma, C | 1 |
| Levy, R | 1 |
| Mathai, M | 1 |
| Chatterjee, P | 1 |
| Ongeri, L | 1 |
| Njuguna, S | 1 |
| Onyango, D | 1 |
| Akena, D | 1 |
| Rota, G | 1 |
| Otieno, A | 1 |
| Neylan, TC | 1 |
| Lukwata, H | 1 |
| Kahn, JG | 1 |
| Cohen, CR | 1 |
| Bukusi, D | 1 |
| Aarons, GA | 1 |
| Burger, R | 1 |
| Blum, K | 1 |
| Nahum-Shani, I | 1 |
| McCulloch, CE | 1 |
| Meffert, SM | 1 |
| Tuttle, JP | 1 |
| Bisson, JI | 2 |
| Baker, A | 1 |
| Dekker, W | 1 |
| Hoskins, MD | 1 |
| Shiner, B | 2 |
| Leonard, CE | 1 |
| Gui, J | 2 |
| Cornelius, SL | 1 |
| Schnurr, PP | 2 |
| Hoyt, JE | 1 |
| Young-Xu, Y | 2 |
| Watts, BV | 2 |
| Yu, YH | 1 |
| Ou, CY | 1 |
| Shyu, BC | 1 |
| Huang, ACW | 1 |
| Vieira, JS | 1 |
| de Souza, GR | 1 |
| Kalil-Cutti, B | 1 |
| Giusti-Paiva, A | 1 |
| Vilela, FC | 1 |
| Browne, CA | 1 |
| Falcon, E | 1 |
| Robinson, SA | 1 |
| Berton, O | 1 |
| Lucki, I | 1 |
| Ariel, L | 1 |
| Inbar, S | 1 |
| Edut, S | 1 |
| Richter-Levin, G | 1 |
| Westgate, CL | 1 |
| Maguen, S | 1 |
| Cosentino, L | 1 |
| Vigli, D | 1 |
| Medici, V | 1 |
| Flor, H | 1 |
| Lucarelli, M | 1 |
| Fuso, A | 1 |
| De Filippis, B | 1 |
| Joseph, A | 1 |
| Tang, M | 1 |
| Mamiya, T | 1 |
| Chen, Q | 1 |
| Yang, LL | 1 |
| Jiao, J | 1 |
| Yu, N | 1 |
| Tang, YP | 1 |
| Han, F | 1 |
| Xiao, B | 1 |
| Wen, L | 1 |
| Shi, Y | 1 |
| Wang, Z | 1 |
| Zhu, K | 1 |
| Chen, L | 1 |
| Ou Yang, L | 1 |
| Huang, Y | 1 |
| Zhao, Y | 1 |
| Youssef, NA | 1 |
| Ara, A | 1 |
| Bhat, I | 1 |
| Kao, CY | 1 |
| He, Z | 1 |
| Zannas, AS | 1 |
| Hahn, O | 1 |
| Kühne, C | 1 |
| Reichel, JM | 1 |
| Binder, EB | 1 |
| Wotjak, CT | 3 |
| Khaitovich, P | 1 |
| Turck, CW | 1 |
| Vafaei, AA | 1 |
| Samaei, SA | 1 |
| Bandegi, AR | 1 |
| Rafiei, A | 1 |
| Valadan, R | 1 |
| Hosseini-Khah, Z | 1 |
| Mohammadkhani, R | 1 |
| Rashidy-Pour, A | 1 |
| Lewis, CC | 1 |
| Simons, AD | 1 |
| Nguyen, LJ | 1 |
| Murakami, JL | 1 |
| Reid, MW | 1 |
| Silva, SG | 1 |
| March, JS | 2 |
| Pinna, G | 3 |
| Haller, J | 1 |
| Nagy, R | 1 |
| Toth, M | 1 |
| Pelczer, KG | 1 |
| Mikics, E | 1 |
| Xu, JJ | 1 |
| Chan, MJ | 1 |
| Yang, YC | 1 |
| Frančišković, T | 1 |
| Suković, Z | 1 |
| Janović, S | 1 |
| Stevanović, A | 1 |
| Nemčić-Moro, I | 1 |
| Rončević-Gržeta, I | 1 |
| Letica-Crepulja, M | 1 |
| Rasmusson, AM | 1 |
| Aykaç, A | 1 |
| Aydın, B | 1 |
| Cabadak, H | 1 |
| Gören, MZ | 1 |
| Hu, X | 1 |
| Li, Y | 1 |
| Hu, Z | 1 |
| Rudd, JA | 1 |
| Ling, S | 1 |
| Jiang, F | 1 |
| Davies, H | 1 |
| Herrmann, L | 1 |
| Ionescu, IA | 1 |
| Henes, K | 1 |
| Golub, Y | 1 |
| Wang, NX | 1 |
| Buell, DR | 1 |
| Holsboer, F | 1 |
| Schmidt, U | 1 |
| Martenyi, F | 5 |
| Brown, EB | 3 |
| Zhang, H | 2 |
| Koke, SC | 2 |
| Prakash, A | 2 |
| Agell, I | 1 |
| Summerfield, D | 1 |
| Davidson, JR | 14 |
| Payne, VM | 1 |
| Connor, KM | 9 |
| Foa, EB | 1 |
| Rothbaum, BO | 1 |
| Hertzberg, MA | 3 |
| Weisler, RH | 1 |
| Harvey, BH | 1 |
| Naciti, C | 1 |
| Brand, L | 1 |
| Stein, DJ | 1 |
| Onder, E | 1 |
| Tural, U | 1 |
| Aker, T | 1 |
| Soldatenkova, V | 1 |
| Siegmund, A | 1 |
| van der Kolk, BA | 2 |
| Spinazzola, J | 1 |
| Blaustein, ME | 1 |
| Hopper, JW | 1 |
| Hopper, EK | 1 |
| Korn, DL | 1 |
| Simpson, WB | 1 |
| Vaishnavi, S | 2 |
| Sheehan, DV | 1 |
| Sheehan, KH | 1 |
| Caldwell, CD | 1 |
| da Rocha, FF | 1 |
| Correa, H | 1 |
| Connor, K | 1 |
| Pibiri, F | 1 |
| Nelson, M | 1 |
| Guidotti, A | 1 |
| Costa, E | 1 |
| Polles, AG | 1 |
| Smith, PO | 1 |
| Marshall, RD | 2 |
| Printz, D | 1 |
| Cardenas, D | 1 |
| Abbate, L | 1 |
| Liebowitz, MR | 1 |
| Dreyfuss, D | 1 |
| Michaels, M | 1 |
| Shera, D | 1 |
| Berkowitz, R | 1 |
| Fisler, R | 1 |
| Saxe, G | 1 |
| Fichtner, CG | 1 |
| Arora, RC | 1 |
| O'Connor, FL | 1 |
| Crayton, JW | 1 |
| Cohen, JS | 1 |
| Glover, H | 1 |
| Colket, JT | 1 |
| Malik, ML | 3 |
| Sutherland, SN | 1 |
| Anton, RF | 1 |
| Burton, JK | 1 |
| Sutherland, SM | 3 |
| Smith, RD | 1 |
| Davison, RM | 1 |
| Tupler, LA | 1 |
| Meltzer-Brody, S | 2 |
| Churchill, E | 2 |
| Cohen, H | 1 |
| Kotler, M | 1 |
| Matar, M | 1 |
| Kaplan, Z | 1 |
| Feldman, ME | 1 |
| Beckham, JC | 1 |
| Kudler, HS | 1 |
| Fernandez, M | 1 |
| Pissiota, A | 1 |
| Frans, O | 1 |
| von Knorring, L | 1 |
| Fischer, H | 1 |
| Fredrikson, M | 1 |
| Agid, O | 1 |
| Shalev, AY | 1 |
| Lerer, B | 1 |
| Barnett, SD | 1 |
| Tharwani, HM | 2 |
| Pohl, R | 1 |
| Balon, R | 1 |
| Burdon, AP | 1 |
| Sutker, PB | 1 |
| Foulks, EF | 1 |
| Crane, MU | 1 |
| Thompson, KE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Sequential, Multiple Assignment Randomized Trial (SMART) for Non-specialist Treatment of Common Mental Disorders in Kenya: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research (DAPPER) Project[NCT03466346] | 2,710 participants (Anticipated) | Interventional | 2020-08-31 | Active, not recruiting | |||
| Treatment for Adolescents With Depression Study (TADS)[NCT00006286] | Phase 3 | 432 participants | Interventional | 1998-09-30 | Completed | ||
| Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) Plus Broad Form of Enhanced Cognitive Behavioural Therapy (CBT-Eb) in Patients With Eating Disorders. A Randomized Controlled Trial[NCT03156959] | 80 participants (Anticipated) | Interventional | 2017-06-19 | Recruiting | |||
| Evaluation of Blended Stepped-care Mental Well-being Intervention for Adults: A Randomized Controlled Trial[NCT05395312] | 402 participants (Anticipated) | Interventional | 2022-07-30 | Active, not recruiting | |||
| Effects of Pregnenolone on Perceived Social Isolation: A Double-blind Randomized Electrical Neuroimaging Study[NCT02826577] | Phase 2 | 96 participants (Anticipated) | Interventional | 2017-05-01 | Active, not recruiting | ||
| Auricular Acupuncture for Sleep Disturbances: A Randomized Control Trial[NCT04956341] | 316 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for fluoxetine and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis.
Topics: Animals; Brain; Disease Models, Animal; Drug Evaluation, Preclinical; Fluoxetine; Humans; Mice; Preg | 2010 |
Post-traumatic stress disorder.
Topics: Antidepressive Agents; Fluoxetine; Humans; Psychotherapy, Psychodynamic; Sertraline; Stress Disorder | 2010 |
Up-regulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioural deficits in a putative mouse model of post-traumatic stress disorder.
Topics: Animals; Anxiety; Behavior, Animal; Brain; Disease Models, Animal; Fluoxetine; Mice; Neurotransmitte | 2012 |
[Three paradigms in the treatment of posttraumatic stress disorder].
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Benzodiazepines; Combat Disorders; Co | 2005 |
Assessment of resilience in the aftermath of trauma.
Topics: Adaptation, Psychological; Allied Health Personnel; Cognitive Behavioral Therapy; Combined Modality | 2006 |
Response characteristics to antidepressants and placebo in post-traumatic stress disorder.
Topics: Antidepressive Agents; Clinical Trials as Topic; Fluoxetine; Humans; Placebo Effect; Placebos; Stres | 1997 |
Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions.
Topics: Alcoholism; Bromocriptine; Dopamine Agonists; Female; Fluoxetine; Humans; Male; Models, Psychologica | 1996 |
Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome.
Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Fluoxetine; Follow-Up S | 2000 |
21 trials available for fluoxetine and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Implementation research for public sector mental health care scale-up (SMART-DAPPER): a sequential multiple, assignment randomized trial (SMART) of non-specialist-delivered psychotherapy and/or medication for major depressive disorder and posttraumatic st
Topics: Adult; Ambulatory Care; Ambulatory Care Facilities; Antidepressive Agents, Second-Generation; Combin | 2019 |
Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Double-Blind Method; Female; Fluo | 2002 |
Trauma, resilience and saliostasis: effects of treatment in post-traumatic stress disorder.
Topics: Adaptation, Psychological; Adult; Cognitive Behavioral Therapy; Female; Fluoxetine; GABA Agonists; H | 2005 |
A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antide | 2006 |
Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: Analysis of the veteran group of a placebo-controlled, randomized clinical trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Double-Blind Method; Female; Fluoxetine; Huma | 2006 |
A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance.
Topics: Adult; Combined Modality Therapy; Depression; Desensitization, Psychologic; Double-Blind Method; Eye | 2007 |
Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study.
Topics: Adult; Antidepressive Agents, Second-Generation; Diagnostic and Statistical Manual of Mental Disorde | 2007 |
Adverse events in PTSD patients taking fluoxetine.
Topics: Akathisia, Drug-Induced; Arousal; Fluoxetine; Humans; Panic Disorder; Prospective Studies; Single-Bl | 1995 |
Fluoxetine in posttraumatic stress disorder.
Topics: Adolescent; Adult; Ambulatory Care; Child; Child Abuse; Child Abuse, Sexual; Double-Blind Method; Fe | 1994 |
Platelet paroxetine binding and fluoxetine pharmacotherapy in posttraumatic stress disorder: preliminary observations on a possible predictor of clinical treatment response.
Topics: Adult; Blood Platelets; Drug Interactions; Fluoxetine; Humans; Kinetics; Male; Middle Aged; Paroxeti | 1994 |
The eight-item treatment-outcome post-traumatic stress disorder scale: a brief measure to assess treatment outcome in post-traumatic stress disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Female; Fluoxetine; Humans; Interview, Psychologica | 1997 |
Response characteristics to antidepressants and placebo in post-traumatic stress disorder.
Topics: Antidepressive Agents; Clinical Trials as Topic; Fluoxetine; Humans; Placebo Effect; Placebos; Stres | 1997 |
Quality of life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo-controlled trial of fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Female; Fluoxetine; Health Status; Humans; Male; Mi | 1999 |
Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Double-Blind Method; Female; Fluoxetine | 1999 |
Derivation of the SPAN, a brief diagnostic screening test for post-traumatic stress disorder.
Topics: Adult; Antidepressive Agents; Cohort Studies; Combat Disorders; Disasters; Female; Fluoxetine; Fluvo | 1999 |
Normalization of heart rate variability in post-traumatic stress disorder patients following fluoxetine treatment: preliminary results.
Topics: Adult; Analysis of Variance; Autonomic Nervous System; Electrocardiography; Female; Fluoxetine; Hear | 2000 |
Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans.
Topics: Aged; Antidepressive Agents, Second-Generation; Dose-Response Relationship, Drug; Double-Blind Metho | 2000 |
Symptom-specific effects of fluoxetine in post-traumatic stress disorder.
Topics: Adult; Arousal; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Psychiatric Stat | 2000 |
Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder.
Topics: Adult; Ambulatory Care; Depression; Drug Administration Schedule; Drug Therapy, Combination; Female; | 2001 |
Tolerability of fluoxetine in posttraumatic stress disorder.
Topics: Administration, Oral; Chi-Square Distribution; Double-Blind Method; Female; Fluoxetine; Humans; Male | 2002 |
Fluoxetine versus placebo in posttraumatic stress disorder.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combat Disorders; Double-Blind Method; Europe | 2002 |
47 other studies available for fluoxetine and Acute Post-Traumatic Stress Disorder
| Article | Year |
|---|---|
Fluoxetine protects against inflammation and promotes autophagy in mice model of post-traumatic stress disorder.
Topics: Animals; Autophagy; Disease Models, Animal; Fluoxetine; Inflammation; Mice; Mice, Inbred C57BL; Stre | 2022 |
Neuronal nitric oxide synthase inhibition accelerated the removal of fluoxetine's anxiogenic activity in an animal model of PTSD.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inh | 2023 |
Effect of combination fluoxetine and exercise on prefrontal BDNF, anxiety-like behavior and fear extinction in a female rat model of post-traumatic stress disorder (PTSD): a comparison with male animals.
Topics: Animals; Anxiety; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Extinction, Psychologic | 2023 |
[Effect of Ganmai Dazao Decoction on ethology of rats with PTSD and its mechanism].
Topics: Animals; Ethology; Fluoxetine; Hippocampus; Maze Learning; Rats; Stress Disorders, Post-Traumatic | 2023 |
Posttraumatic Stress Disorder: Evaluation and Treatment.
Topics: Fluoxetine; Humans; Selective Serotonin Reuptake Inhibitors; Sertraline; Stress Disorders, Post-Trau | 2023 |
Geraniol attenuates behavioral and neurochemical impairments by inhibitions of HPA-axis and oxido-inflammatory perturbations in mice exposed to post-traumatic stress disorder.
Topics: Acetylcholinesterase; Animals; Corticosterone; Disease Models, Animal; Fluoxetine; Hippocampus; Hypo | 2023 |
Clinical Case Conference: A Woman with Alcohol Use Disorder and PTSD Case Report.
Topics: Adult; Alcohol-Induced Disorders; Antidepressive Agents; Depression; Female; Fluoxetine; Humans; Mid | 2019 |
Evidence-based prescribing for post-traumatic stress disorder.
Topics: Evidence-Based Medicine; Fluoxetine; Humans; Paroxetine; Sertraline; Stress Disorders, Post-Traumati | 2020 |
Comparing Medications for DSM-5 PTSD in Routine VA Practice.
Topics: Acute Disease; Adult; Carbonic Anhydrase Inhibitors; Female; Fluoxetine; Humans; Male; Medication Ad | 2020 |
Basolateral Amygdala but Not Medial Prefrontal Cortex Contributes to Chronic Fluoxetine Treatments for PTSD Symptoms in Mice.
Topics: Animals; Basolateral Nuclear Complex; Fear; Fluoxetine; Mice; Prefrontal Cortex; Stress Disorders, P | 2020 |
Post-traumatic stress disorder increases pain sensitivity by reducing descending noradrenergic and serotoninergic modulation.
Topics: Adrenergic Neurons; Animals; Behavior, Animal; Fluoxetine; Male; Norepinephrine; Pain; Pain Manageme | 2021 |
Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine.
Topics: Animals; Behavior, Animal; Brain; Buprenorphine; Disease Models, Animal; Excitatory Amino Acid Antag | 2018 |
Fluoxetine treatment is effective in a rat model of childhood-induced post-traumatic stress disorder.
Topics: Age Factors; Animals; Behavior, Animal; Disease Models, Animal; Fluoxetine; Male; Rats; Rats, Spragu | 2017 |
A Retrospective Comparative Effectiveness Study of Medications for Posttraumatic Stress Disorder in Routine Practice.
Topics: Adult; Anticonvulsants; Female; Fluoxetine; Humans; Male; Medical Records; Middle Aged; Outpatients; | 2018 |
Methyl-CpG binding protein 2 functional alterations provide vulnerability to develop behavioral and molecular features of post-traumatic stress disorder in male mice.
Topics: Animals; Avoidance Learning; Conditioning, Psychological; Corticosterone; Epigenomics; Fluoxetine; G | 2019 |
Temporal association of elevated cholecystokininergic tone and adolescent trauma is critical for posttraumatic stress disorder-like behavior in adult mice.
Topics: Analysis of Variance; Animals; DNA Primers; Electric Stimulation; Enzyme-Linked Immunosorbent Assay; | 2013 |
Effects of fluoxetine on the amygdala and the hippocampus after administration of a single prolonged stress to male Wistar rates: In vivo proton magnetic resonance spectroscopy findings.
Topics: Amygdala; Animals; Aspartic Acid; Choline; Creatine; Fluoxetine; Hippocampus; Male; Proton Magnetic | 2015 |
Preventive effects of ginsenoside Rg1 on post-traumatic stress disorder (PTSD)-like behavior in male C57/B6 mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Corticotropin-Releasing Hormone; D | 2015 |
Does dose-response relationship further support the concept of posttraumatic OCD.
Topics: Accidents, Traffic; Adult; Bipolar Disorder; Combat Disorders; Dose-Response Relationship, Drug; Flu | 2016 |
Fluoxetine treatment prevents the inflammatory response in a mouse model of posttraumatic stress disorder.
Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Calcium-Binding Proteins; Disease Models, | 2016 |
Effects of moderate treadmill exercise and fluoxetine on behavioural and cognitive deficits, hypothalamic-pituitary-adrenal axis dysfunction and alternations in hippocampal BDNF and mRNA expression of apoptosis - related proteins in a rat model of post-tr
Topics: Animals; Apoptosis; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cognition; Cognition Disord | 2017 |
Impact of childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study (TADS).
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Child Abuse; Child Abuse, Sexual; Cogni | 2010 |
NR2B subunit-specific NMDA antagonist Ro25-6981 inhibits the expression of conditioned fear: a comparison with the NMDA antagonist MK-801 and fluoxetine.
Topics: Animals; Ataxia; Disease Models, Animal; Dizocilpine Maleate; Electroshock; Excitatory Amino Acid An | 2011 |
Fluoxetine as a treatment for post-traumatic stress disorder.
Topics: Antidepressive Agents, Second-Generation; China; Databases, Factual; Female; Fluoxetine; Humans; Mal | 2011 |
Tianeptine in the combined treatment of combat related posttraumatic stress disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety; Combat D | 2011 |
The change in muscarinic receptor subtypes in different brain regions of rats treated with fluoxetine or propranolol in a model of post-traumatic stress disorder.
Topics: Adrenergic beta-Antagonists; Amygdala; Animals; Anxiety; Blotting, Western; Brain Chemistry; Explora | 2012 |
The alteration of 5-HT(2A) and 5-HT(2C) receptors is involved in neuronal apoptosis of goldfish cerebellum following traumatic experience.
Topics: Analysis of Variance; Animal Fins; Animals; Antidepressive Agents, Tricyclic; Apoptosis; bcl-Associa | 2012 |
Long-lasting hippocampal synaptic protein loss in a mouse model of posttraumatic stress disorder.
Topics: Animals; Antidepressive Agents, Second-Generation; Arousal; Carrier Proteins; Fear; Fluoxetine; Hipp | 2012 |
Fluoxetine in relapse prevention of PTSD.
Topics: Fluoxetine; Humans; Recurrence; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Trau | 2003 |
War, exile, moral knowledge and the limits of psychiatric understanding: a clinical case study of a Bosnian refugee in London.
Topics: Bosnia and Herzegovina; Culture; Fluoxetine; Humans; Male; Middle Aged; Psychiatry; Refugees; Select | 2003 |
Serotonin and stress: protective or malevolent actions in the biobehavioral response to repeated trauma?
Topics: Animals; Behavior; Fenclonine; Fluoxetine; Maze Learning; Memory; Psychomotor Performance; Rats; Rec | 2004 |
A mouse model of posttraumatic stress disorder that distinguishes between conditioned and sensitised fear.
Topics: Administration, Oral; Animals; Arousal; Association Learning; Conditioning, Classical; Depression; D | 2007 |
Perceived stress in anxiety disorders and the general population: a study of the Sheehan stress vulnerability scale.
Topics: Adult; Anti-Anxiety Agents; Clinical Trials as Topic; Clonazepam; Cross-Sectional Studies; Female; F | 2007 |
Was the exacerbation of PTSD symptoms after high doses of venlafaxine due to the noradrenergic mechanism? A case report.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Female; Fluoxetine; Humans; Middle Aged; Se | 2007 |
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials.
Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disord | 2007 |
Decreased corticolimbic allopregnanolone expression during social isolation enhances contextual fear: A model relevant for posttraumatic stress disorder.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Animals; Brain Chemistry; Cerebral Cortex; Fear; Fluoxetine; | 2008 |
Treatment of coexisting substance dependence and posttramatic stress disorder.
Topics: Adult; Alcoholism; Behavior Therapy; Combined Modality Therapy; Comorbidity; Fluoxetine; Humans; Ill | 1995 |
Provide fluoxetine information vital to clinicians.
Topics: Fluoxetine; Humans; Periodicals as Topic; Research Design; Stress Disorders, Post-Traumatic | 1995 |
Critique of fluoxetine study in PTSD.
Topics: Bias; Fluoxetine; Humans; Research Design; Stress Disorders, Post-Traumatic; Terminology as Topic | 1996 |
Categorizing fear: the role of trauma in a clinical formulation.
Topics: Adult; Child; Child Abuse, Sexual; Fear; Female; Fluoxetine; Humans; Life Change Events; Psychothera | 1999 |
Brain function in a patient with torture related post-traumatic stress disorder before and after fluoxetine treatment: a positron emission tomography provocation study.
Topics: Anxiety; Cerebrovascular Circulation; Fear; Fluoxetine; Humans; Male; Selective Serotonin Reuptake I | 2001 |
SPRINT: a brief global assessment of post-traumatic stress disorder.
Topics: Adult; Chronic Disease; Female; Fluoxetine; Humans; Male; Middle Aged; Personality Assessment; Psych | 2001 |
Davidson Trauma Scale (DTS): normative scores in the general population and effect sizes in placebo-controlled SSRI trials.
Topics: Adult; Clinical Trials as Topic; Effect Modifier, Epidemiologic; Female; Fluoxetine; Humans; Male; M | 2002 |
Antidepressants, panic disorder, and PTSD.
Topics: Adult; Desipramine; Female; Fluoxetine; Humans; Panic Disorder; Stress Disorders, Post-Traumatic | 1992 |
Fluoxetine and fluvoxamine in PTSD.
Topics: Adult; Drug Evaluation; Fluoxetine; Fluvoxamine; Humans; Male; Serotonin; Stress Disorders, Post-Tra | 1992 |
Pilot program of treatment for PTSD.
Topics: Amitriptyline; Behavior Therapy; Combined Modality Therapy; Family Therapy; Fluoxetine; Humans; Male | 1991 |
Discussion of fluoxetine and suicidal tendencies.
Topics: Ambulatory Care; Depressive Disorder; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetin | 1990 |